NeoPharm Investors' Class Action Trimmed
A federal judge has narrowed the allegations in an investor class action against biopharmacuetical company NeoPharm Inc. over allegedly false and misleading statements about the cancer drug liposome-encapsulated paclitaxel....To view the full article, register now.
Already a subscriber? Click here to view full article